6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
A series of 6alpha-alkyl-substituted analogues of chenodeoxycholic acid (CDCA) were synthesized and evaluated as potential farnesoid X receptor (FXR) ligands. Among them, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) was shown to be a very potent and selective FXR agonist (EC(50) = 99 nM) and to be endowed with anticholeretic activity in an in vivo rat model of cholestasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A bile acid receptor (FXR) agonist has reached the market since this programme started: obeticholic acid (Ocaliva), which was discovered by GSK in collaboration with the University of Perugia51 and subsequently developed by Intercept Pharmaceuticals.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [51]
In the citing paper
“OCA is a farnesoid X receptor (FXR) agonist that is 100 times more potent than the endogenous ligand, chenodeoxycholic acid.(156)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [156]
In the citing paper
“Obeticholic acid has approximately 100 times greater potency in activating FXR than chenodeoxycholic acid. 11”
From A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis (2016) · cites this paper as [11]
In the citing paper
“Obeticholic acid is a selective farnesoid X receptor (FXR) agonist that is derived from the bile acid chenodeoxycholic acid, the endogenous FXR ligand.”
From A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis (2016) · cites this paper as [11]
In the citing paper
“OCA, a 6α-ethyl derivate of chenodeoxycholic acid, is a steroidal FXR agonist (still maintaining its BA structure) and first-in-class therapeutic FXR ligand.94”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [94]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Self-citationNuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis
Goodwin, B., Jones, S. A., Price, R. R., Watson, M. A., McKee, D. D., Moore, L. B., Galardi, C., Wilson, J. G., Lewis, M. C., Roth, M. E., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00051-4 · Cited by 1,940
Self-citationTargeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR
Wang, H., Chen, J., Hollister, K., Sowers, L. C., & Forman, B. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80348-2 · Cited by 1,636
Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators
McKenna, N. J., & O'Malley, B. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00641-4 · Cited by 1,463
The Continuing Importance of Bile Acids in Liver and Intestinal Disease
Hofmann, A. F. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.22.2647 · Cited by 982
Modulation of Polyketide Synthase Activity by Accessory Proteins During Lovastatin Biosynthesis
Kennedy, J., Auclair, K., Kendrew, S. G., Park, C., Vederas, J. C., & Richard Hutchinson, C. (1999) · Science · doi:10.1126/science.284.5418.1368 · Cited by 654
Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR
Maloney, P. R., Parks, D. J., Haffner, C. D., Fivush, A. M., Chandra, G., Plunket, K. D., Creech, K. L., Moore, L. B., Wilson, J. G., Lewis, M. C., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0002127 · Cited by 527
Self-citation
Research works printed but not linked: 3
- Mangelsdorf D. J., 1995, Cell, 83, 850
- Forman B. M., 1995, Cell, 81, 693
- Lu T. T., 2000, Mol. Cell, 6, 515
Cited by
Items 601–700 of 793
Yang, M., Lin, R., Zhang, X., Li, G., Wang, Q., Li, C., Xiao, Y., Wei, L., & Bi, H. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127834 · Cited by 9
Obeticholic acid for the treatment of primary biliary cirrhosis
Yimam, K. K., & Bowlus, C. L. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.964206 · Cited by 5
“demonstrated that OCA not only promotes bile flow but also protects hepatocytes against acute necrosis caused by lithocholic acid [16].”
BackgroundInfluentialAntidiabetic Sulfonylureas Modulate Farnesoid X Receptor Activation and Target Gene Transcription
Steri, R., Kara, M., Proschak, E., Steinhilber, D., Schneider, G., & Schubert‐Zsilavecz, M. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.10 · Cited by 5
Update in the Care and Management of Patients with Primary Sclerosing Cholangitis
Sedki, M., & Levy, C. (2018) · Current Gastroenterology Reports · doi:10.1007/s11894-018-0635-8 · Cited by 5
Merk, D., Grisoni, F., Schaller, K., Friedrich, L., & Schneider, G. (2018) · ChemistryOpen · doi:10.1002/open.201800270 · Cited by 4
Sahu, R., Mishra, R., & Majee, C. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1797485 · Cited by 5
“A major breakthrough toward the synthetic bile acid compounds was the discovery of the potent and selective FXR agonist OCA, which was designed based on the structure of CDCA but with 100-fold greater activity [88].”
BackgroundCroce, A. C., Ferrigno, A., Palladini, G., Mannucci, B., Vairetti, M., & Pasqua, L. G. D. (2023) · Molecules · doi:10.3390/molecules28093818 · Cited by 5
Makishima, M., & Yamada, S. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-381978-9.10079-4 · Cited by 5
Zhang, Y., Ning, G., Handelsman, Y., & Bloomgarden, Z. T. (2009) · Journal of Diabetes · doi:10.1111/j.1753-0407.2009.00056.x · Cited by 8
Identifying farnesoid X receptor agonists by naïve Bayesian and recursive partitioning approaches
Ding, Q., Li, C., Wang, L., Li, Y., Zhou, H., Gu, Q., & Xu, J. (2015) · MedChemComm · doi:10.1039/c5md00149h · Cited by 5
Finamore, C., Festa, C., Barbato, R., Fiorucci, S., Zampella, A., & Marino, S. D. (2025) · ChemMedChem · doi:10.1002/cmdc.202500405 · Cited by 5
Self-citationCurley, C. E., Lajczak, N., Adorini, L., Chonghaile, T. N., & Keely, S. J. (2025) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00086.2025 · Cited by 4
Hasan, M. N., Wang, H., Luo, W., Clayton, Y. D., Gu, L., Du, Y., Palle, S. K., Chen, J., & Li, T. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100649 · Cited by 4
“Obeticholic acid (OCA, Ocaliva) is a potent farnesoid x receptor (FXR) agonist approved by the FDA in 2016 as a second line drug for patients with PBC who do not respond adequately to or cannot tolerate UDCA treatment (5 – 8).”
BackgroundYang, Y., Jiao, L., Huang, Y., Shang, H., Li, E., Chang, H., Cui, H., & Wan, Y. (2025) · Environmental Health Perspectives · doi:10.1289/ehp15435 · Cited by 4
Garg, A., Vasandani, C., Li, X., Quittner, C., & Yokoo, T. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf173 · Cited by 5
Farnesoid X receptor agonism – a new approach to the treatment of cholesterol gallstone disease
Doggrell, S. A. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.4.535 · Cited by 4
“Bile acid derivatives are also being developed as FXR agonists and antagonists [7,8], and 6-α-ethyl-chenodeoxycholic acid (6-ECDCA, Figure 1) is a potent and selective FXR agonist (EC50 = 99 nM) [7].”
BackgroundLeitch, A. C., Probert, P. M. E., Shayman, J. A., Meyer, S. K., Kass, G. E. N., & Wright, M. C. (2017) · Toxicology · doi:10.1016/j.tox.2017.05.014 · Cited by 4
Cai, Z., Wang, B., Zhou, Z., Zhao, X., Hu, L., Ren, Q., Deng, L., Li, Z., & Wang, G. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14014 · Cited by 4
“Bile acid is the endogenous ligand of FXR (chenodeoxycholic acid, CDCA; Figure 1; Pellicciari et al., 2002), which regulates inflammation and protecting the liver (Cipriani et al., 2010; Hollman et al., 2012; Li & Guo, 2015; Ryan et al., 2014).”
BackgroundLee, E. J., Kim, Y., Kim, J., Yoon, E. L., Lee, S. R., & Jun, D. W. (2022) · Life · doi:10.3390/life13010100 · Cited by 4
Finamore, C., Baronissi, G., Marchianò, S., Leva, F. S. D., Carino, A., Monti, M. C., Limongelli, V., Zampella, A., Fiorucci, S., & Sepe, V. (2019) · Molecules · doi:10.3390/molecules24061043 · Cited by 4
“In the frame of steroidal family, the introduction of an ethyl group at C-6 on the CDCA ring B afforded the disclosure of 6-ethylchenodeoxycholic acid (6-ECDCA/INT-747/obeticholic acid/Ocaliva/OCA, Figure 1) [21], the most potent steroidal FXR agonist generated so far, that showed also a GPBAR1 activity (EC50 = 0.”
BackgroundSelf-citationVázquez‐Gómez, S., Vázquez-Tato, M. P., Seijas, J. A., Meijide, F., de Frutos, S., & Tato, J. V. (2019) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2019.112092 · Cited by 4
Transcriptional Regulation of Hepatobiliary Transporters
Karpen, S. J. (2004) · Springer eBooks · doi:10.1007/978-1-4419-9034-1_8 · Cited by 4
Potenza, M., Cavalluzzi, M. M., Milani, G., Lauro, G., Carino, A., Roselli, R., Fiorucci, S., Zampella, A., Pierri, C. L., Lentini, G., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104897 · Cited by 4
Self-citationStygar, D. M., Bogielski, B., Michalczyk, K., Skrzep-Poloczek, B., Suchocka, A., Nikiel, K., Kukla, K., Wasek, R., Staniszewski, J., Matyja, M., et al. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1788973 · Cited by 4
Regulation of Hepatobiliary Transporters During Liver Injury
Manautou, J. E., & Ghanem, C. I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95661-7 · Cited by 3
Wei, C., Wu, J., Zhang, C., Zhao, Y., Li, C., & Yang, X. (2023) · Exploration of Digestive Diseases · doi:10.37349/edd.2023.00031 · Cited by 2
A Collection of Novel Antitumor Agents That Regulate Lipid Metabolism in the Tumor Microenvironment
Zhang, J., Xu, S., Yue, L., Lei, H., & Zhai, X. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02809 · Cited by 3
He, Q., Jiang, M., Wang, Y., & Zheng, T. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70186 · Cited by 3
“…a bile acid analogue with high affinity for FXR, which efficiently reduces the synthesis, uptake and absorption of bile salts by activating FXRs. 7,13 It is worth noting that AKP is among main criteria of diagnosis and clinical therapeutic effects for PBC. 8,14 OCA was the world's first drug that…”
Yu, X., Zhang, Y., Wu, B., Zhao, B., & Wang, C. (2025) · Drug Metabolism Reviews · doi:10.1080/03602532.2025.2558654 · Cited by 4
“…different genomic targets, suggesting a nuanced interaction between FXR and its ligands. it has been observed that structural modifications in the side chain at position c-17 of cDcA may be linked to the selective regulation of downstream target gene functions by FXR (Pellicciari et al. 2002).”
Porez, G., Prawitt, J., Gross, B. S., & Staels, B. (2012) · Cited by 3
Yang, H., & Park, C. (2016) · The Korean Journal of Obesity · doi:10.7570/kjo.2016.25.4.167 · Cited by 3
“It was first described in 2002 as a potent and selective steroidal FXR agonist.(32) In animal studies, OCA reverses insulin resistance and hepatic steatosis, inhibits gluconeogenesis and lipogenesis, and also shows anti-inflammatory and anti-fibrotic activities.”
BackgroundLi, X., Zhang, H., Li, C., Zheng, W., Wang, M., Wu, M., Yang, D., Hu, Y., Huo, D., Xu, Z., et al. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.905 · Cited by 3
“798 Clinical Pharmacology in Drug Development 2021, 10(7)”
BackgroundInfluentialUp-to-Date Snapshot of Current and Emerging Medical Therapies in Primary Biliary Cholangitis
Warsop, Z. I., Anand, N., Maliki, H. A., Souza, S. D., Kamyab, A. A., Hadad, A. A., & Alrubaiy, L. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14121133 · Cited by 4
“OCA is derived from the primary human BA chenodeoxycholic acid [45].”
On the Pharmacology of Farnesoid X Receptor Agonists: Give me an "A", Like in "Acid"
Hambruch, E., Kinzel, O., & Kremoser, C. (2016) · Nuclear Receptor Research · doi:10.11131/2016/101207 · Cited by 3
Emerging drugs for the treatment of primary biliary cholangitis
Phaw, N. A., Dyson, J. K., & Jones, D. E. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1751814 · Cited by 4
Chapter 1 Regulation of Metabolism by Nuclear Hormone Receptors
Huang, H.-J., & Schulman, I. G. (2009) · Progress in molecular biology and translational science · doi:10.1016/s1877-1173(09)87001-4 · Cited by 4
Molecular mechanisms of cholestasis
Trauner, M., Fickert, P., Halilbasic, E., Wagner, M., & Zollner, G. (2007) · Springer eBooks · doi:10.1007/1-4020-4144-6_20 · Cited by 3
Abdelzaher, W. Y., Khalaf, H. M., Ahmed, S. M., Attya, M. E., Mohamed, A., Ali, A. M. M., Gaber, S. S., Abdelhakeem, A. M., Mohammed, E. M., & Hassan, M. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-00986-0 · Cited by 2
“OCA and its derivatives have been demonstrated in earlier research to reduce the release of proinflammatory cytokines in acute liver failure, osteoarthritis and cardiac toxicity [16, 32, 33].”
Kang, D., Li, A. Q., Xie, X., Liu, H., Chen, L., Feng, Z., Gao, X., Gao, H., Wu, X., Lu, H., et al. (2026) · MedComm · doi:10.1002/mco2.70637 · Cited by 3
Mohamed, M. A.-E., Rihan, S., Elbakry, M. M. M., & Moselhy, S. S. (2024) · Natural Product Research · doi:10.1080/14786419.2024.2316328 · Cited by 2
“…agonist that controls the expression of transcription factors that decrease the production of bile acids and the amount of steatosis in the liver (Pellicciari et al. 2002; Jiao et al. 2015). oCA has been demonstrated to reduce liver inflammation in the FlINT trial (NCT01265498), with no…”
Microbial metabolites as a way to provide crosstalk between gut and liver
Nitert, M. D., & Ovadia, C. (2024) · Obstetric Medicine · doi:10.1177/1753495x241258383 · Cited by 2
Qiu, X., Li, W., Li, X., Wu, B., Dai, M., Xia, Y., Zhang, G., Bian, Y., Chen, J., Wu, K., et al. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c03743 · Cited by 2
Integrating deep learning and molecular dynamics simulations for FXR antagonist discovery
Yang, Y., Huang, Y., Shen, H., Wang, D., Liu, Z., Zhu, W., & Liu, Q. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11145-2 · Cited by 2
“…developed, including bile acid derivatives obtained through structural modification [e.g., obeticholic acid (OCA)] and non-steroidal compounds identified via high-throughput screening (HTS) combined with combinatorial chemistry and lead optimization (e.g., GW4064, fexaramine, WAY362450) [10, 11].”
Joythi, R. K., Chandrasekhar, K. B., Balakrishnan, B. M., & Kiran, B. S. S. (2020) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.54.2s.92 · Cited by 2
Tanaka, A., Leung, P. S. C., Bowlus, C. L., & Gershwin, M. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-51709-0_22 · Cited by 2
Farnesoid X receptor as a therapeutic target for dyslipidemia
Evans, M. J., & Gardell, S. J. (2009) · Clinical Lipidology · doi:10.2217/clp.09.51 · Cited by 2
Bile Acid-Derived Vitamin D Receptor Ligands
Makishima, M., & Yamada, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809963-6.00088-2 · Cited by 2
Development of Nuclear Receptor Modulators
Schierle, S., & Merk, D. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8630-9_14 · Cited by 3
New therapeutic perspectives in non-alcoholic steatohepatitis
Ampuero, J., Sanchez-Torrijos, Y. M., Aguilera, V., Bellido, F., & Romero‐Gómez, M. (2018) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2017.07.016 · Cited by 7
Clinical Patterns of Primary Biliary Cholangitis: Comparison Between Two European Case Series
Abenavoli, L., Procopio, A. C., Cinaglia, P., Zanza, C., Grazie, C. D., Longhitano, Y., Libicherová, P., & Luzza, F. (2022) · Reviews on Recent Clinical Trials · doi:10.2174/1574887117666220617095856 · Cited by 2
Nagunuri, G. C. L., Katangoor, V., Surigilla, V., Sajja, E., Srinivasan, T. R., & Mathad, V. T. (2022) · Organic Process Research & Development · doi:10.1021/acs.oprd.2c00237 · Cited by 2
Novel preclinical developments of the primary sclerosing cholangitis treatment landscape
Sohal, A., & Kowdley, K. V. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2330738 · Cited by 4
“In a rat model, obeticholic acid (OCA) was associated with reduction in liver injury caused by the administration of lithocholic acid (LCA) [37].”
BackgroundFloreani, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-65908-0_8 · Cited by 2
Cho, K., Park, J. Y., Han, J., & Jeong, T. (2003) · Lipids · doi:10.1007/s11745-003-1173-y · Cited by 3
Sorribas, M., Jakob, M. O., Yilmaz, B., Li, H., Stutz, D., Noser, Y., Gottardi, A. D., Moghadamrad, S., Hassan, M., Albillos, A., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/690057 · Cited by 2
Hepatobiliary Transport of Bile Acids
Kagawa, T. (2017) · Springer eBooks · doi:10.1007/978-4-431-56062-3_2 · Cited by 1
Bile Acids and Metabolic Syndrome
Taoka, H., & 渡辺, 光. (2017) · Springer eBooks · doi:10.1007/978-4-431-56062-3_15 · Cited by 1
Hu, Q., Liu, C., Tan, J., Wang, J., Yang, H., Liu, Y., Mao, H., Jiang, Z., Feng, X., & Tao, X. (2025) · Pharmaceuticals · doi:10.3390/ph18060809 · Cited by 1
“CDCA is a hydrophobic compound derived from animal gallbladders and is characterized by high biocompatibility and low toxicity [22].”
Hasan, M. N., Wang, H., Luo, W., Du, Y., Xiong, L., Gu, L., & Li, T. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100936 · Cited by 1
Passeri, D., Cerra, B., Carotti, A., Greco, F. A., Piermarini, S., Colliva, C., Liscio, P., Franco, F., Adorini, L., Erickson, M. R., et al. (2026) · ChemMedChem · doi:10.1002/cmdc.202500960 · Cited by 2
Self-citationDivenko, M., & Mills, J. C. (2026) · Physiological Reviews · doi:10.1152/physrev.00033.2025 · Cited by 4
Histamine and Pruritus: From Molecular Mechanisms to Clinical Therapy
Lan, Y., Guo, J., Yao, M., Liao, Z.-R., & Jing, Y. (2026) · Cell Biochemistry and Function · doi:10.1002/cbf.70199 · Cited by 1
Li, J., de Vries, H. D., Ustyantsev, K., Hovingh, M. V., Mulder, N. L., Havinga, R., Huijkman, N., Falcone, S., de Bruyn, K., Weersing, E., et al. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101088 · Cited by 1
Bowlus, C. L., Nevens, F., Kowdley, K. V., Bonder, A., Capozza, T. A., Li, J., Nair, R., Trauner, M., & Jones, D. E. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70832 · Cited by 2
Ali, A. H., Carey, E. J., & Lindor, K. D. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.908701 · Cited by 1
“Obeticholic acid (OCA) (or 6a-ethyl chenodeoxycholic acid [CDCA]) [68] is a novel derivative of the bile acid CDCA, the natural ligand for the FXR.”
BackgroundBile Acid as Therapeutic Agents
Yamanashi, Y., Takada, T., & Suzuki, H. (2017) · Springer eBooks · doi:10.1007/978-4-431-56062-3_5 · Cited by 1
Rizzo, G., Passeri, D., Franco, F., Ciaccioli, G., Donadio, L., Rizzo, G., Orlandi, S., Sadeghpour, B. M., Wang, X. X., Jiang, T., et al. (2010) · Journal of Hepatology · Cited by 1
Zhang, L., Chen, Y., & Li, W. (2025) · Chemical Research in Chinese Universities · doi:10.1007/s40242-024-4210-6 · Cited by 1
Li, L., Ren, X., Gao, X., Zhao, Y., Ma, Y., Gong, J., Yang, S., Sun, Y., & Wang, Y. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02656-w · Cited by 1
“Both bile acids improve hepatic function, regulate cholesterol metabolism, and mitigate inflammation, with established clinical applications in NAFLD and primary biliary cholangitis [18–20].”
Investigating Fibroblast Growth Factor 19 expression in primary and secondary bile acid diarrhoea
Nolan, J. (2016) · doi:10.25560/41879 · Cited by 1
Primary Biliary Cholangitis: Its Science and Practice
Wang, L., Bowlus, C. L., Wang, F., & Gershwin, M. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-50168-0_8 · Cited by 2
Gai, K., Huang, Y., Liu, B., & Zhang, Y. (2018) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3643 · Cited by 1
Discovery, Structural Refinement and Therapeutic Potential of Farnesoid X Receptor Activators
Lamers, C., & Merk, D. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788015783-00076 · Cited by 1
Tanaka, A., & Gershwin, M. E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00058-0 · Cited by 2
Bile Acid Induced Diarrhoea Pathophysiological and Clinical Aspects
Bajor, A. (2008) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1
Nuclear Hormone Receptor Medicinal Chemistry
Cheng, P. T. W., Kick, E. K., & Mukherjee, R. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc191 · Cited by 1
Short Article Structural Basis for Bile Acid Binding and Activation of the Nuclear Receptor FXR
Mi, L.-Z., Devarakonda, S., Harp, J. M., Han, Q., Pellicciari, R., Willson, T. M., Khorasanizadeh, S., & Rastinejad, F. (2003) · Cited by 1
Self-citationPrimary Biliary Cholangitis (Formerly Primary Biliary Cirrhosis)
Trivedi, P. J., & Hirschfield, G. M. (2019) · Wiley eBooks · doi:10.1002/9781119211419.ch38 · Cited by 1
Therapeutic Approaches for Nonalcoholic Steatohepatitis ( NASH )
Glatthar, R., & Arch, R. H. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc274 · Cited by 1
Orphan drugs in development for primary biliary cirrhosis: challenges and progress
Lindor, K. D., Ali, A. H., & Byrne, T. (2015) · Orphan Drugs Research and Reviews · doi:10.2147/odrr.s69477
“151,152 Collectively, these effects could be of therapeutic benefit to patients with cholestatic liver diseases.”
Structure/Function Studies of the Androgen Receptor DNA-Binding Region
Rastinejad, F. (2001) · Defense Technical Information Center (DTIC) · doi:10.21236/ada398061
Neue Aspekte zur Pathogenese der NASH
Stremmel, W., Pathil‐Warth, A., & Chamulitrat, W. (2010) · Die Gastroenterologie · doi:10.1007/s11377-009-0373-4
Alexander, S. P. H., Mathie, A. A., & Peters, J. A. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706511
Macchiarulo, A., Carotti, A., Cellanetti, M., Sardella, R., & Gioiello, A. (2012) · MedChemComm · doi:10.1039/c2md20157g
The role of the farnesoid X receptor in metabolic control
Stroeve, J. H. M. (2011) · University of Groningen research database (University of Groningen / Centre for Information Technology)
DEVELOPMENTAL REGULATION OF THE DRUG-PROCESSING GENOME IN MOUSE LIVER
Cui, Y. J. (2010) · KU ScholarWorks (The University of Kansas)
Treatment of primary biliary cirrhosis
Poupon, R. Y., & Corpechot, C. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.870031
“While the latter BA is the most potent natural activator of human FXR, the key nuclear receptor for homeostasis and enterohepatic circulation of BAs, OCA is 100 times more potent as an FXR agonist [116].”
BackgroundRizzo, G., Passeri, D., Franco, F., Ciaccioli, G., Donadio, L., Rizzo, G., Orlandi, S., Sadeghpour, B. M., Wang, X. X., Jiang, T., et al. (2010)
Alexander, S., Mathie, A. A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_6.x
Bile acid receptors as targets for drug
Schaap, G., Trauner, M. A., & Jansen, P. L. M. (2013)
Claudel, T., Sturm, E., Staels, B., & Kuipers, F. (2003) · CRC Press eBooks · doi:10.3109/9780203481165-8
methylation and KRAS signaling FXR silencing in human colon cancer by DNA
Kopetz, S., Powis, G., Kiriakova, G. L. G., Izzo, J. G., Wei, C., Bailey, M. H., Maru, D. M., Shureiqi, I., & Pickering, C. R. (2016)
Targets and investigative treatments for primary biliary cholangitis
Ali, A. H., Carey, E. J., & Lindor, K. D. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1227240
“bile flow and protection of hepatocytes against necrosis caused by lithocholic acid [71].”
BackgroundNeues Therapiekonzept für die primär-biliäre Cholangitis (PBC)
Schmitz, F. (2016) · Die Gastroenterologie · doi:10.1007/s11377-016-0120-6
Future Therapies for Primary Sclerosing Cholangitis
Lammert, C. S., & Vuppalanchi, R. (2016) · Springer eBooks · doi:10.1007/978-3-319-40908-5_12 · Cited by 1
The Systems Biology of Transporters – Targeting the Regulatory System for Transporters (FXR/RXR)
Gioiello, A., Marinozzi, M., Cerra, B., Custodi, C., Pellicciari, R., & Macchiarulo, A. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527679430.ch9
Self-citationBile Acids and Cholestatic Liver Disease 2: Primary Sclerosing Cholangitis
Nakazawa, T. (2017) · Springer eBooks · doi:10.1007/978-4-431-56062-3_8
Potent stimulation of Fibroblast Growth Factor 19 expression in the human
Zhang, J. H., Nolan, J., Kennie, S. L., Johnston, I. M., Dew, T. K., Dixon, P. H., Williamson, C., & Walters, J. R. F. (2013)
Colliva, C. (2013) · AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna) · doi:10.6092/unibo/amsdottorato/5612
Advances in treatment options for patients with primary biliary cholangitis
Parés, A. R. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1394840
“Obeticholic acid (6-alpha-ethyl-chenodeoxycholic acid, OCA) is a synthetic derivative of chenodeoxycholic acid [49], being 100 times more potent as a farnesoid-X-receptor (FXR) agonist.”
Background
Metadata
- Authors
- Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M.
- Affiliations
- University of Perugia (IT)
- Corresponding author
- Pellicciari, Roberto
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2002-07-20
- Volume
- 45
- Issue
- 17
- Pages
- 3569-3572
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2049515100
- Cited by
- 743
- References
- 15
- Citations by year
- 2026: 20 · 2025: 33 · 2024: 32 · 2023: 33 · 2022: 46 · 2021: 47 · 2020: 54 · 2019: 46 · 2018: 52 · 2017: 60 · 2016: 49 · 2015: 38 · 2014: 35 · 2013: 27 · 2012: 31
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- farnesoid X receptor agonist, cholestasis, bile acid synthesis inhibition, receptor selectivity
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Anticholesteremic Agents, Cell Line, Chenodeoxycholic Acid, Cholestasis, DNA-Binding Proteins, Humans, Ligands, Liver, Structure-Activity Relationship, Transcription Factors, Rats, Wistar, Receptors, Cytoplasmic and Nuclear, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.